10-Q · May 14, 2026
Curanex Pharmaceuticals reported no revenue in Q1 2026, consistent with the same quarter in 2025. The company recorded a significant net loss of $3,150,228, up from a loss of $137,583 in the prior year, reflecting…
Earnings analysis · 10-Q
CURX earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include the income statement, balance sheet, cash flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed. The…
Read full summary
The provided 10-Q extract does not include the income statement, balance sheet, cash flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed. The principal disclosed issue is that disclosure controls and procedures were not effective as of the end of the reporting period. The company reported 0 pending legal proceedings and 0 unregistered equity sales, but provided no quantitative guidance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
No Pending Legal Proceedings
The company reported 0 pending legal proceedings involving the company or specified related parties in the filing.
-
No Unregistered Equity Sales
There were 0 unregistered equity sales during the period covered by the Quarterly Report.
-
No Insider Trading Plan Changes
No directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
What to watch
-
Ineffective Disclosure Controls
As of the end of the period covered by the Quarterly Report, management concluded that disclosure controls and procedures were not effective to provide reasonable assurance over timely recording, processing, summarization, reporting, and communication of required information.
-
Risk-Factor Update Unavailable
The filing states that Item 1A risk-factor disclosure is not required because the company is a smaller reporting company, so the provided 10-Q does not identify specific changes versus the prior filing.
-
Control Remediation Not Evident
The company states that no changes during the period covered by the Quarterly Report materially affected, or were reasonably likely to materially affect, internal control over financial reporting; however, disclosure controls remained ineffective as of June 30, 2026.
Management's outlook
The provided 10-Q extract contains no quantitative revenue or EPS outlook. Numeric guidance is not provided.
Earlier filings 3
10-K · March 30, 2026
Curanex is a development-stage botanical-drug company advancing its lead candidate Phyto-N through preclinical CMC and toxicology work toward an IND targeted for Q4 2026. The company completed a GMP pilot-scale batch in…
10-Q · November 17, 2025
Curanex reported no revenue and a Q3 2025 net loss of $954,059 (three months ended September 30, 2025) versus a net loss of $91,166 in Q3 2024; diluted EPS was $(0.04) for the quarter. The company completed an IPO and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.